Nigeria’s medicine supply chain and Africa’s deepening pharmaceutical import reliance have come under renewed scrutiny as The Alternative Bank (AltBank) unveils a financing intervention aimed at reshaping the country’s healthcare production landscape and strengthening long-term medicine security.
Across the continent, Africa carries roughly a quarter of the global disease burden yet depends on external markets for nearly 97 percent of its pharmaceutical commodities; a structural weakness that was sharply exposed during the COVID-19 pandemic when global supply chains were disrupted and access to essential drugs became uncertain.
In Nigeria, the consequences of this dependence have remained persistent, with local healthcare systems highly vulnerable to foreign exchange pressures, import delays and global price volatility. Against this backdrop, AltBank is positioning itself as a catalytic financier for domestic pharmaceutical production through asset-backed, risk-sharing capital models designed to unlock industrial-scale manufacturing capacity.
As part of this strategy, the bank has extended a formal engagement invitation to Industrial Pharmacists across Nigeria, seeking collaboration to accelerate local production, strengthen supply chains and reduce reliance on imported medicines.
Speaking in a recent interview with the Association of Industrial Pharmacists of Nigeria (NAIP) for the maiden edition of its Pharma Industry Digest, Jekwu Ozoemene, group executive at The Alternative Bank, emphasised that pharmaceutical independence is now a national priority.
“Pharma and medicine security and sovereignty is essential to Nigeria’s survival. We are positioned to partner with all stakeholders to make this a reality,” Ozoemene stated.
The bank, which operates as a fully licensed non-interest financial institution, is deploying what it describes as “patient capital”; a financing approach structured around asset-backed and risk-sharing principles that align repayment schedules with the actual cash flow realities of businesses, rather than rigid traditional loan structures.
Under this model, AltBank is targeting pharmaceutical manufacturers, distributors, logistics operators and research institutions with tailored financial products aimed at closing long-standing funding gaps in the sector.
These offerings include stock financing, vendor and distributor financing, supply chain financing and revolving drug fund solutions. The institution is also extending support through ecosystem enablers such as health insurance schemes, health management information systems, capital market access and Banking-as-a-Service platforms.
According to the bank, these interventions are being expanded in partnership with State Health Boards to improve the availability of quality medicines while simultaneously reducing costs for end users.
Beyond immediate healthcare delivery improvements, AltBank argues that strengthening domestic pharmaceutical production could have significant macroeconomic benefits for Nigeria.
By reducing dependence on imported medicines, the initiative is expected to ease pressure on foreign exchange demand, support currency stability and improve overall external sector resilience.
At the same time, scaling local pharmaceutical manufacturing is projected to create jobs across multiple segments of the value chain, including laboratory research, clinical testing, quality assurance, production engineering, logistics and retail distribution, thereby deepening industrial linkages within the economy.
Ozoemene stressed that the bank’s ambition extends beyond conventional trade financing and import substitution models, focusing instead on building full industrial capacity within Nigeria’s healthcare ecosystem.
“We don’t only want to finance the company that imports the most products. We also want to finance the industrial pharmacist establishing a WHO-compliant manufacturing plant to produce essential medicines locally. We want to back the researcher working on new formulations for malaria treatments or hypertension drugs designed specifically for the Nigerian demographic,” he explained.
AltBank’s model also aligns closely with the principles of non-interest banking, which prioritises ethical investment structures and socially impactful financing over speculative returns. By directing capital toward life-saving infrastructure and essential services, the bank says it is reinforcing its mandate as a development-oriented financial catalyst.
The growing urgency around pharmaceutical sovereignty is further reinforced by recurring medicine shortages, high import costs and limited domestic production capacity, which have continued to challenge Nigeria’s healthcare system despite its large consumer base and growing demand for essential drugs.
As stakeholders across finance, healthcare and industry increasingly converge around local production solutions, AltBank’s intervention signals a deeper rethinking of how financial systems can directly support national health security and economic resilience.
